EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues

Exelixis (EXEL) reported mixed Q2 2025 results, with adjusted EPS of $0.75 surpassing estimates but total revenues of $568.3 million missing expectations and declining 10.8% year-over-year. The revenue shortfall was primarily driven by a 70% drop in collaboration income, offsetting a robust 18.8% increase in net product revenues, led by strong Cabometyx sales and initial demand from its new NET indication. Despite pre-market stock weakness due to the revenue miss, the company maintained its 2025 guidance, highlighted positive late-stage pipeline data for zanzalintinib, and reached a patent settlement allowing a Cabometyx generic entry from January 2031.

Analysis

Exelixis reported mixed Q2 2025 results, characterized by an earnings beat and a revenue miss that masks underlying operational strength. While total revenue fell 10.8% year-over-year to $568.3 million, missing consensus estimates, this decline was entirely attributable to a 70% drop in collaboration revenues due to a difficult comparison against a $150 million milestone payment in the prior-year quarter. Core business performance was robust, with net product revenues growing 18.8% to $520 million, driven by strong sales volume for its flagship drug Cabometyx. The new NET indication for Cabometyx already constitutes over 4% of demand, signaling a new growth driver. Critically, the company maintained its full-year 2025 guidance, suggesting confidence in second-half acceleration. This outlook is bolstered by significant pipeline progress, including positive top-line results from the late-stage STELLAR-303 study for zanzalintinib, which demonstrated a statistically significant improvement in overall survival. This de-risks the company's long-term succession plan for Cabometyx. Furthermore, a patent settlement with Biocon has provided long-term clarity, deferring generic competition in the U.S. until January 2031, while an active share repurchase program continues to return capital to shareholders.

Key Decisions for Investors

• Investors should look past the headline revenue miss, as it was driven by a non-recurring collaboration payment comparison, and instead focus on the strong 18.8% growth in core product revenues.
• The initial pre-market stock weakness may present a tactical opportunity, as the positive overall survival data from the zanzalintinib STELLAR-303 trial represents a significant de-risking event for the company's pipeline and long-term growth narrative.
• Monitor the sales trajectory from the new NET indication for Cabometyx and upcoming pipeline milestones for zanzalintinib, as these are the key catalysts for achieving maintained full-year guidance and justifying valuation.
• The patent litigation settlement providing clarity on Cabometyx exclusivity until 2031 significantly extends the company's runway to commercialize its pipeline, a key positive factor for long-term models.